A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease.

Despite efforts by test maker Grail to highlight outcomes the company considers positive, some experts are warning against using the Galleri test and others like it.

LAS VEGAS -- Former UFC middleweight champion Anderson Silva has failed a second drug test administered by the Nevada State Athletic Commission. NSAC executive director Bob Bennett confirmed to ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

The recent results of Indiana’s ILEARN test highlight the systemic issues inherent in these assessments. Indiana Learning Evaluation and Readiness Network tests students in grades 3 through 8 in ...